Status:
TERMINATED
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Non-small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent ...
Eligibility Criteria
Inclusion
- For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
- ECOG Performance Status (PS) \<=1
- Histologically or cytologically confirmed, stage IIIB (malignant pleural effusion), stage IV or recurrent NSCLC
- Measurable disease by RECIST guidelines
Exclusion
- Evidence of predominantly squamous-cell histology
- Known CNS metastases
- Any prior antineoplastic systemic regimens for NSCLC
- Excessive risk of bleeding (including use of therapeutic anticoagulation) and history of thrombotic or embolic cerebrovascular accident
- Gross hemoptysis (≥1/2 tsp of red blood)
- Uncontrolled hypertension
- Clinically significant cardiovascular disease
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
- Serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00850577
Start Date
June 1 2009
End Date
August 1 2013
Last Update
October 12 2015
Active Locations (55)
Enter a location and click search to find clinical trials sorted by distance.
1
Acrc/Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States, 85715
2
Sharp Clinical Oncology Research
San Diego, California, United States, 92123
3
Cancer Institute Of Florida
Orlando, Florida, United States, 32804
4
Palm Beach Cancer Institute
West Palm Beach, Florida, United States, 33401